cyrilzakka/clinical-trials huggingface dataset:
Getting Ahead for Cancer Control

A new, practical program, entitled Getting Ahead in a Just-Gettin'-By World, provides a novel approach to addressing this previously intractable problem. During the progression through the Getting Ahead program, individuals develop an understanding of the hidden rules of economic class and have an opportunity to craft a hopeful future story based on the practical concepts investigated in the modules. Getting Ahead has shown great success in various organizations and communities in multiple sectors, including healthcare, but has not been studied in the context of advancing cancer prevention and control.

The study team hypothesizes that the Getting Ahead program, applied in safety net practices with primary care patients living in poverty, will improve cancer prevention and early detection activities, mediated by a shift in future orientation gained through the program.

This pilot study aims to adapt, apply, and evaluate the established Getting Ahead program in a health care setting and assess its effect on cancer prevention and early detection activities for vulnerable populations. By generating process and outcome data on a novel intervention to help people advance out of poverty, this research will set the stage for larger intervention studies, and also will advance understanding of the mechanisms by which growing a future orientation can improve cancer preventive service delivery among vulnerable populations.

Specifically, this study aims to:

1. Implement Getting Ahead among cohorts of patients at a network of safety net practices.
2. Assess the paradigm shift in developing a future orientation associated with participation in the Getting Ahead program.
3. Evaluate the effect of the Getting Ahead program and its associated paradigm shift on graduates' cancer prevention and early detection activities.

Eligibility Criteria:
Inclusion Criteria:

* Interest and willingness to commit to the 8 week Getting Ahead training program that will occur over 16 sessions occurring twice a week
* Willingness to commit to follow-up with his/her primary care provider after completion of the Getting Ahead training program
* Willingness to be randomized to an immediate or delayed (by 8 weeks) start date
* Ability to speak English

Exclusion Criteria:

* There are no exclusion criteria
Suspected Deficient Activation of Vitamin D in Patients With Secondary Hyperparathyroidism

The purpose of this study is to determine if a reduction in the enzyme 1-hydroxylase, which activates Vitamin D, is the cause of overactivity of the parathyroid glands (called secondary hyperparathyroidism - normal blood calcium and elevated parathyroid hormone) in a selected group of young patients with normal kidney function.

Vitamin D, an essential nutrient, is produced by the skin after sunlight shines on it. Vitamin D must then be activated by both the liver and the kidneys to perform its function of maintaining strong bones and helping to prevent heart disease, infection, diabetes and cancer. Reduced kidney activation of Vitamin D occurs with advanced age and with all kidney diseases. We have identified a small group of patients who appear to have reduced ability of the kidneys to activate vitamin D, even though they are young and do not have chronic kidney disease. In these patients, we are comparing the ability of their kidneys to activate Vitamin D to that of healthy controls. To stimulate the kidneys to activate Vitamin D, we are giving parathyroid hormone intravenously over 8 hours and collecting blood and urine at baseline, 4 and 8 hours. This type of parathyroid infusion does not cause side effects. The gene that controls this activation is also being studied (by a simple blood test) to look for abnormalities. We are now actively recruiting healthy controls for this study.

Eligibility Criteria:
Inclusion Criteria:

* Caucasian female
* Age 40-59 years
* Serum creatinine \< 1.3 and estimated glomerular filtration rate (GRF) \> 60
* Serum calcium in the normal range (for U Md lab 8.6-10 mg/dl)
* Parathyroid hormone in the normal range (for U Md lab 12-54 pg/ml)
* Normal 25-hydroxyvitamin D level (30 ng/ml or higher)
* For women of childbearing age, non-pregnant (based on negative urine pregnancy test on the morning of the teriparatide infusion)

Exclusion Criteria:

* Non-caucasian
* Age under 40 and over 59 years
* Male
* Serum creatinine over 1.3 or estimated glomerular filtration rate (GFR) \< 60
* Abnormal serum calcium (for U Md lab, below 8.6 or above 10 mg/dl)
* Abnormal parathyroid hormone (for U Md lab, above 65 or below 12 pg/ml)
* For women of childbearing age, non-pregnant (based on urine pregnancy test on the morning of the teriparatide infusion)
* History of bone radiation
* History of Paget disease of bone
* History of bone malignancy or metastases
* History of allergy or sensitivity to Forteo
Biomarkers in Blood Samples From Patients With HIV Infection and Stage III or Stage IV Hodgkin Lymphoma Undergoing Chemotherapy

RATIONALE: Studying samples of blood in the laboratory from patients undergoing treatment with HIV infection and Hodgkin lymphoma may help doctors learn more about the effects of therapy on HIV.

PURPOSE: This research study is studying biomarkers in blood samples from patients with HIV infection and stage III or stage IV Hodgkin lymphoma undergoing chemotherapy.

OBJECTIVES:

Primary

* To quantify HIV-1 persistence in prospectively collected samples from patients on suppressive antiretroviral therapy undergoing chemotherapy for Hodgkin lymphoma.

OUTLINE: This is a multicenter study.

Blood samples are collected before, during, and after treatment for lymphoma for HIV-1 RNA levels using standard and single copy assays and HIV-1 DNA quantification (peripheral blood mononuclear cells).

After completion of treatment, patients are followed up periodically for up to 2 years.

Eligibility Criteria:
DISEASE CHARACTERISTICS:

* HIV-1 infection, as documented by a rapid HIV test or any FDA-approved HIV-1 enzyme or chemiluminescence immunoassay (E/CIA) test kit and confirmed by western blot at any time prior to study entry

  * Documentation may be serologic (positive ELISA and positive western blot), or other federally approved licensed HIV diagnostic test
  * Prior documentation of HIV seropositivity is acceptable
* Diagnosis of untreated Hodgkin lymphoma and participation in the parent protocol SWOG-S0816, "A Phase II Trial of Response Adapted Therapy of Stage III-IV Hodgkin Lymphoma Using Early Interim FDG-PET Imaging."

PATIENT CHARACTERISTICS:

* No psychosocial conditions that would prevent study compliance and follow-up, as determined by the principal investigator
* Willing to provide serial blood samples

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
A Phase I Study of G3139 Subcutaneous in Solid Tumors

Genasense® is currently administered to subjects in clinical studies as a multiple-day continuous intravenous infusion. Subjects are treated on an outpatient basis and carry a pump that delivers the drug through a peripheral or central intravenous line. The route of administration limits the convenience of treatment, and catheter-related complications have been reported. This study is designed to evaluate the pharmacokinetics and safety of G3139 administered by subcutaneuous injection.


Eligibility Criteria:
Inclusion Criteria:

* A Confirmed diagnosis of a solid tumor malignancy, not to include lymphoma, that has failed standard therapy or for which no standard therapy is available. Patients with a history of brain metastasis will be eligible if there is no evidence of cerebral edema or treatment with steroids.
* Adequate organ function as determined \< 7 days prior to starting study medication
* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2
* At least 3 weeks and recovery from effects of major prior surgery or other therapy including radiation therapy, immunotherapy, cytokine, biological, vaccine and chemotherapy

Exclusion Criteria:

* Significant medical diesese
* History of leptomeningeal disease
* Coexisting condition that would require the subject to continue therapy during the treatment phase of the study with a drug known to alter renal function.
* Use of any investigational drug within 3 weeks prior to starting study medication
* Known hypersensitivity to phosphorothioate-containing oligonucleotides
* Pregnancy/Lactation
Effect of Probe Placement in Delivery Room on Temperature at the Admission of Premature Infants?

The aim of the study is to compare the effect of 3 different skin temperature placement probe in the case room on the admission temperature to the NICU in preterm infants. The authors aim to evaluate which placement results in more preterm in the acceptable range (36.5-37 °C).

It's a prospective randomized trial conducted at Maisonneuve Rosemont Hospital, neonatal tertiary center located in Montreal with over 2600 annual deliveries. All pregnant women who are expecting to deliver a preterm infant with gestational between 28 and 35 6/7 weeks will be eligible to be enrolled into the study and informed consent is obtained.

Simple randomization is accomplished by opening a sealed pre-set envelope with group assignment before delivery.

Group 1: The probe is placed lateral from the spine, 1 cm above the intergluteal cleft, and in side position to the flank between the hips and the ribs.

Group 2: The probe is placed on the chest, 1 cm above the left nipple. Group 3: The probe is placed deep in the left axilla

At birth, all the preterm are immediately placed under a radiant warmer and resuscitated as per Neonatal resuscitation program (NRP) guidelines. Application of a skin temperature probe set at 36.5°C, for servo-controlled thermoregulation by 2 minutes of life. Probes will be fixed with an insulated reﬂective water-soluble gel probe.

No changes are made to the routine delivery room management and resuscitation for this study. After initial delivery room management, babies are transported in a heated radiant warmer (Panda) to the NICU.

In the delivery room, when the baby has a skin temperature servo-controlled stable at 36.5° C, the baby is ready to be transferred to NICU. All babies admitted to the NICU are routinely cared for by the attending neonatologist.

Data collection:

The temperature displaced on the servo controlled table is collected when the baby is the NICU just before transfer from the radiant table to the incubator.

The right axillary temperature will be taken by a thermometer.

Eligibility Criteria:
Inclusion criteria:

* Preterm infant with gestational age between 28 and 35 6/7 weeks

Exclusion criteria:

* Infant with severe congenital malformation and those who had sever asphyxia or died in the delivery room and infant born before arrival of NICU team.
The Assessment of Acute /Chronic Phase in Patients With Ischemic Cerebral Stroke Using TCM Diagnostic Tools

Cerebral infarction is the second cause of death and the third cause of disability. More than 13.7 million patients worldwide are diagnosed with stroke every year, and the number of deaths is 5.5 million, of which ischemic stroke is the major type, accounting for 87%. Sequelae of stroke are problems that require long-term medical care. If we can intervene and assist with Traditional Chinese Medicine (TCM) at early stage, it will be a great boon for patients. In clinical practice, TCM collects data as the basis for diagnosis through the four diagnostic methods-look, listen, question, and feel the pulse. Among these, tongue diagnosis and pulse diagnosis belong to the categories of look and feel the pulse. At present, the objective examination instruments of TCM developed are mainly tongue diagnostic instruments and pulse diagnostic instruments. Therefore, we hope to utilize tongue and pulse diagnoses as the main reference to analyze the changes in ischemic stroke stages. The data of this study are collected from China Medical University Hospital and YuanRung Hospital-for further statistical analysis. Ischemic stroke patients (ICD-10: I63) who were hospitalized within 1 week from the date of diagnosis were eligible to join this research project. Tongue and pulse examinations were collected once per week within 1 month. A total of 4 tongue-pulse examinations were collected in each case, which were categorized into acute stage (24 hours to 1 week), subacute stage (1 to 3 weeks) and chronic stage (more than 3 weeks). \[30\] This research is to study the changes of tongue and pulse diagnoses in acute, subacute and chronic stages among ischemic patients who receive TCM diagnosis and treatment. Through utilizing objective evaluation of Chinese and Western medical examination instruments, we hope to establish clear diagnostic standards for TCM syndrome types, so as to evaluate the efficacy of clinical diagnosis and treatment. The goal is to improve the quality of TCM care and to provide Chinese and Western integrated treatment for stroke patients in the future. This research can also serve as a reference for related TCM research and development.


Eligibility Criteria:
Inclusion Criteria:

1. Patients older than 40 years of age, who acted in concert with the complete examination and answered the questionnaire.
2. Participants were diagnosed as ischemic stroke (ICD-10：I63) by neurologist, and were approved by head CT or MRI examination.
3. Those with a stable vital sign after being examined by an internal medicine specialist
4. Those who experience a cerebral vascular accident within 10 days of the consultation
5. Signing the agreement document to join the research program

Exclusion Criteria:

1. Those with an unstable vital sign
2. Patients who were unable to protrude their tongue or the protruding length was insufficient
3. Those at risk of jaw dislocation
4. Those with an arteriovenous shunt or fistula
5. Those who experience seizures
6. Those with poor cognition and communication
Short-term Effects of Postural Taping on Pain and Neck Posture

The aim of this study was to investigate the effects of a short treatment period with Balance Body Tape on the intensity of perceived neck, shoulder and back pain and neck posture.

The aim of this study was to investigate the effects of a short treatment period with Balance Body Tape on the intensity of perceived neck, shoulder and back pain and neck posture.

Method 26 subjects who reported being university students or having a sedentary work and experiencing pain in neck, back or shoulders were randomized into intervention- (n=12) and control group (n=14).

The intervention group received a three-week treatment with BBT, the control group received no treatment. A questionnaire regarding pain, including a Numeric Rating Scale (NRS) measuring pain intensity, and a Photographic posture analysis measurement (PPAM) of habitual sitting posture were accomplished before and after the intervention for both groups. Wilcoxon´s signed rank test and Mann-Whitney U test was used to assess intra- and between group differences respectively. The relationship between pain intensity and CV-angle was assessed using Spearman's rank-order correlation.

Eligibility Criteria:
Inclusion Criteria:

* Aged 18-39
* University student or having a sedentary work
* Experienced of neck, shoulder and/or back pain, during prolonged sitting
* Minimum of 2-point score at the Numeric Rating Scale.

Exclusion Criteria:

* Severe back or neck injuries within the last 3 months
* Ongoing treatment plan for any back or neck problems
* Severe contact allergy or eczema
* Previously tried Body Balance Tape.
Study of Low-Magnitude, High-Frequency Vibration Treatment on Osteoporotic Hip Fracture Healing

Osteoporotic hip fracture is common in elderly. As a result of aging population in Hong Kong, the total number of hip fracture cases is anticipated to increase substantially in the future, and therefore draw more resources in hospitals and healthcare cost. Osteoporotic hip fracture usually causes severe pain and takes long time (4-8months) to recover due to impaired healing capability in osteoporotic bones and limited mobility. Consequently, the patients will recover very slowly as a result of low physical activities to provide inadequate mechanical stimulation. It is also known that mechanical, vascular and biological factors are the keys for fracture healing.

Low-magnitude, high-frequency vibration (LMHFV) treatment is a biophysical intervention to provide whole-body vibration signals for mechanical stimulation, which has been proven to be good in enhancing bone and muscle performance, as well as blood circulation. Our previous study of LMHFV on femoral fracture in rats showed acceleration of fracture healing, resulted from enhanced callus formation and maturation. Application of LMHFV on osteoporotic fractures could shorten the period of complete callus bridging by 30%. Our clinical trial on normal elderly also demonstrated improved muscle performance with good compliance, which is also a critical factor for fracture healing.

In this study, the investigators therefore hypothesize that LMHFV can enhance hip fracture healing by enhancing fracture impaction, maintaining bone mineral density, enhancing muscle recovery, thus improving implant mechanical stability and rehabilitation in elderly patients. The hip fracture elderly patient will be recruited and randomized into control or treatment group. They will be assessed on the fracture healing at fixed time point. The findings of this study will provide very useful scientific data to support the application of LMHFV for hip fracture patients.The ultimate goal is to enhance the fracture healing and rehabilitation in elderly patients.


Eligibility Criteria:
Inclusion Criteria:

* unilateral hip fracture patients older than 65 years old
* patient fixed with dynamic hip screw

Exclusion Criteria:

* unstable vital signs, large amount of drainage, or wound infection postoperatively
* having of hormone replacement therapy or drug treatment known to affect bone metabolism or cause spontaneous bone loss
* having hypo- or hyperparathyroidism and hypo-, hyperthyroidism, renal or liver disease
* cannot tolerate or complication occurs during study
* patients whose fracture is due to underlying disease, secondary to malignancy
Out-of Hospital Resuscitation Study

Sudden cardiac arrest is one of the most common causes of death in industrial countries. The main objective of this study is to built up a register of all out-of hospital resuscitation in a defined area. According to this register, it is possible to evaluate for example predictors of survival to improve training and organisation of prehospital resuscitations.


Eligibility Criteria:
Inclusion Criteria:

* out of hospital cardiac arrest

Exclusion Criteria:

* none
A Phase 1 Study of the Safety and Pharmacokinetics of AGS-16M18 in Subjects With Advanced Renal Cell Cancer

This is a first in human study of AGS-16M18 given every week to subjects with advanced renal cell cancer. AGS-16M18 will be administered as a 60 minute IV infusion on consecutive days until the disease worsens.

Subjects will be enrolled sequentially into 5 planned dose cohorts according to a standard, dose escalation study design. A disease assessment will be performed at study week 5 (+/- 3 days) by the investigator. The assessment will be based both on changes in clinical symptoms, and radiographic images. Subjects without evidence of disease progression may receive AGS-16M18 extended therapy at the dose and schedule of their assigned cohort until disease progression or intolerability of AGS-16M18. Disease assessments will be performed every 8 weeks during the extended period. A safety follow-up visit will occur 4 weeks after the last infusion of AGS-16M18.

Eligibility Criteria:
Inclusion Criteria:

* Histologic or cytologic diagnosis (recent or remote) of metastatic renal cell carcinoma (including papillary, clear cell, and excluding transitional cell types) that is not amendable to cure by surgery or other means, and must have failed at least one prior systemic therapy, including but not limited to treatment with sunitinib, temsirolimus or sorafenib
* Evaluable/Measureable disease according to Response Criteria for Solid tumors
* Eastern Cooperative Group performance status of 0-1
* Therapeutic anti-coagulation (PT, and/or INR, PTT) permitted, if clinically stable and \>/= 3 months from initiation

Exclusion Criteria:

* Past or present documented central nervous system (CNS) tumor or CNS metastasis
* Use of investigational drug (including marketed drugs not approved for this indication) within 4 weeks prior to screening or 5 half-lives of the prior investigational drug (whichever is longer)
* History of thromboembolic events and bleeding disorders \</= 3 months (e.g., DVT or PE)
* Major Surgery (that requires general anesthesia) within 4 weeks of study enrollment
Influence of Serum Vitamin D Levels on Embryo Morphokinetic Parameters

The aim of this study is observing the relation between serum Vitamin D levels and morphokinesis of time lapse monitored Day 5 embryo in between 18 and 38 years age women undergoing controlled ovarian hyperstimulation (COH) because of unexplained or tubal factor infertility. Individuals will be divided into 2 groups according to serum vitamin D levels as normal or low , and the influence of those levels in morphokinetic parameters of embryos will be identified.

Up to date there are few studies questioning the serum Vitamin D deficiency as a negative factor for pregnancy rates in women undergoing COH cycles and also are displaying different and inconclusive results. This dedicated negative affects may be mediated through endometrial and/or ovarial factors. In experimental animal models Vitamin D receptors have been found in endometrium and ovaries and deficient levels might have been a cause of impaired folliculogenesis. In one of human study Vitamin D has been suggested as a positive regulator of anti- Mullerian hormone (AMH) production. Therefore, we aimed to clarify the affects of Vitamin D on folliculogenesis, oogenesis and embryo quality in COH cycles by using time lapse monitoring.

Eligibility Criteria:
Inclusion Criteria:

* 18 years to 38 years age, 2 or less in vitro fertilization (IVF) / intracytoplasmic sperm injection (ICSI) attempt history, Unexplained or tubal factor infertility, Serum Follicle Stimulating Hormone (FSH) \< 10, Antral Follicule Count (AFC)\> 6-8

Exclusion Criteria:

* Male factor infertility, Presence of endometriosis or adenomyosis,Diminished ovarian reserve